Serina Therapeutics, Inc. (SER) stock
Close on Nov 10, 2026Market cap $36.32MP/E –Yield –
Serina Therapeutics, Inc. grew revenue 132.1% to $130.00K over fiscal 2025. Free cash flow was -$21.20M. At the latest close the market valued the company at $36.32M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $36.32M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -58.37%
Fundamentals
- Revenue
- $130.00K
- Net income
- -$21.18M
- EPS, diluted
- -$1.90
- Free cash flow
- -$21.20M
- Diluted shares
- 16M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $1.43
- Open
- $1.43
- Day's range
- $1.39 – $1.53
- Volume
- 44,582
- Average volume (20 days)
- 73,490
- Beta (5 years)
- 0.36
- 52-week range
- $1.14 – $4.31
- RSI (14 days)
- 37.8
- Volatility (1 year)
- 139.6%
- Relative volume
- 0.27×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 10, 2026. The S&P 500 is measured by the SPY fund.
| Period | SER | S&P 500 | Difference | SER per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.5% | -3.7% | −24.8 pts | ||
| 3 months | -46.4% | -2.7% | −43.7 pts | ||
| Year to date | -25.2% | +10.8% | −36.1 pts | ||
| 1 year | -64.2% | +11.2% | −75.4 pts | ||
| 3 years | +141.1% | +76.5% | +64.7 pts | +34.1% | +20.8% |
| 5 years | +76.5% | +72.9% | +3.6 pts | +12.0% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Serina Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- Update
- News
About Serina Therapeutics
Pharmaceutical Preparations
Serina is a clinical-stage biotechnology company that develops polymer-based drug therapies for neurological disorders and other conditions. The company utilizes a proprietary poly(2-oxazoline) polymer delivery platform to attach and release therapeutics, such as small molecules, antibody-drug conjugates, and lipid nanoparticles for ribonucleic acid vaccines. Its drug development pipeline includes SER-252, an injectable dopamine agonist conjugate under clinical investigation for advanced Parkinson’s disease, and SER-214 for early-stage disease. Serina targets patients requiring sustained drug release and collaborates with biopharmaceutical companies seeking polymer technologies for drug delivery applications.
Company profile, executives and historySerina Therapeutics stock: common questions
What is Serina Therapeutics's stock price?
SER closed at $1.43 on Nov 10, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.14 and $4.31.
What is Serina Therapeutics's market cap?
Serina Therapeutics was worth $36.32M at the close on Nov 10, 2026: the share price times the diluted shares outstanding.
What is SER's P/E ratio?
Serina Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.90), so it has no meaningful P/E ratio.
How much revenue does Serina Therapeutics make?
Serina Therapeutics reported revenue of $130.00K for fiscal 2025, up 132.1% from a year earlier.
Does Serina Therapeutics pay a dividend?
No. Serina Therapeutics has not paid a cash dividend over the last twelve months.
When does Serina Therapeutics report earnings next?
Serina Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has SER stock performed over the past year?
Including dividends, SER returned -64.2% over the past year, against +11.2% for the S&P 500.
How many SER shares are sold short?
0M shares were sold short at the latest FINRA report, 0.37% of the float, or 1.0 days of average trading volume.
Who are Serina Therapeutics's competitors?
Companies most similar to Serina Therapeutics by business, industry and size include CLNN, LSTA, CRVO, SNGX, IXHL.
See a number that looks wrong?